ProCE Banner Activity

HPTN 084: Long-Acting Injectable Cabotegravir Superior to Daily Oral TDF/FTC for HIV PrEP in Cisgender Women

Slideset Download
Conference Coverage
Monthly cabotegravir injections were associated with an 89% lower risk of HIV infection vs daily oral TDF/FTC; both strategies were generally safe and well tolerated, with no discontinuations for injection-site reactions.

Released: January 30, 2021

Expiration: January 29, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Gilead Sciences, Inc.

Janssen Therapeutics Division of Janssen Products

Merck Sharp & Dohme Corp.

ViiV Healthcare

Partners

IAS 2018

ProCE Banner

IAS 2021 HIV R4P

ProCE Banner